Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Ex Input:
Paragraph: Costs of theMRIdian on-table adaptive radiotherapy in comparison to conventional radiotherapy are not discussed. Given that it is new and more personalized than current treatment options it's likely to be correspondingly more expensive. Certainly, more frequent MRIs would be very costly. The release provides exact information about increased survival rates in the cohorts of individuals treated with the adaptive versus the convention radiotherapy techniques. "The cohort receiving a higher dose demonstrated a near doubling of median overall survival (Kaplan-Meier estimated median overall survival of 27.8 months compared to 14.8 months)." The news release provides specific results regarding experiences of both groups with regard to toxicity from radiotherapy. We appreciate that the headline of this release starts with the words "early data" because this report deals with preliminary and retrospective research. It was not a clinical trial. Instead, results are based on retrospectively comparing treatment of two groups of patients at four institutions. Respective comparisons can't account for a host of factors that might influence results. At the end of the news release readers are told that on the basis of these promising results a clinical trial is being planned. With five-year survival rates of 1 to 14%, it would be hard to engage in disease mongering about pancreatic cancer. This research was sponsored by ViewRay, the company that developed the MRIdian system, and the release does a good job calling attention to this. However, according to the published study, at least one of the co-authors received honoraria from ViewRay Medical Systems. Since this was not included in the release we're rating this criteria Not Satisfactory. This study was all about comparing alternatives, so it scores Satisfactory on that criterion. It would have helped readers if alternatives would have been described more in laymen's terms. The news release notes that the next step is a prospective clinical trial and that tells savvy readers that this treatment strategy has a long road of testing ahead. Still, we think the release could have done a better job clarifying that this therapy is not yet ready for patients, outside of the clinical trial. A study that suggests a doubling of median survival is sure to capture the attention of patients newly diagnosed with pancreatic cancer. These patients and their families are closely aware of the glum statistics for the disease. This is a practical concern that the release should have touched on. This technology is indeed novel and unique to ViewRay, though it is becoming available in more and more cancer treatment centers. No unjustifiable language was identified in the news release. Claim: Early data shows nearly 2x prolonged median survival for inoperable pancreatic cancer

Ex Output:
This news release reports results of a retrospective study comparing conventional radiotherapy for inoperable pancreatic cancer versus an adaptive radiation therapy that allows clinicians to see the tumor in real time and respond to changes on a daily basis. Targeting the tumor more specifically means higher doses of radiation can be used without increasing damage to surrounding tissues. The study, funded by ViewRay, maker of the MRIdian system, is admittedly preliminary. It is to be followed up by a clinical trial. The release would have been more helpful to readers had it mentioned costs and disclosed a conflict of interest between one of the study authors and the device manufacturer. Surgery is an option only for certain less common types of pancreatic cancer. The five-year survival rates for pancreatic cancers that cannot be treated with surgery are 12% to 14% even for those diagnosed in stage I; the five-year survival rate for cancers detected at stage IV is about 1%, according to the American Cancer Society. ACS reminds readers that five-year survival rates are estimates and that "many people live longer often much longer than 5 years." In that context, a treatment that could extend the lives of the 1.5% of Americans who develop pancreatic cancer is big news.

Ex Input:
Paragraph: Prime Minister Shinzo Abe declared a state of emergency in Tokyo and six other prefectures last week in response to the coronavirus outbreak. While many businesses in Tokyo and elsewhere are now shut, most convenience stores have stayed open as they are considered essential. There are around 58,000 convenience stores throughout Japan. Most are open 24 hours and sell everything from pre-made bento lunches to beer and neckties. They also offer package delivery and bill payment services. "I actually feel safer," said 53-year-old restaurant owner Isao Otsuka, who was shopping at one of the roughly 150 7-Eleven stores, mainly in Tokyo, that have installed the transparent plastic curtains. 7-Eleven's owner, Seven & i Holdings, has asked convenience store workers to wear masks, check their temperatures, wash their hands frequently and sterilise surfaces. The new coronavirus spreads from person to person through small droplets from the nose or mouth via coughing or sneezing, according to the World Health Organization. Scientists have also said the virus can remain infectious in droplets in the air for hours and on surfaces for days. Japan had recorded 7,411 cases of infection and 138 deaths from the virus as of Monday, public broadcaster NHK said, with more than 2,000 cases in Tokyo, a sharp rise from late March. Claim: With plastic sheets, Japan's convenience stores target social distancing.

Ex Output:
Some of Japan's ubiquitous convenience stores have taken a novel approach to social distancing by hanging plastic sheets from the ceiling to provide a barrier between customers and staff at the cash register during the coronavirus pandemic.

Ex Input:
Paragraph: The company said it had received expedited approvals from regulators to trial the drug - an inhaled formulation of interferon-beta-1a - in hospital patients who have COVID-19, the disease caused by the virus. Explaining the drug's mechanism, Chief Executive Richard Marsden said interferon-beta was a naturally occurring protein instrumental to the body's antiviral responses. "Interferon-beta is like the conductor of the orchestra, you make it when you've got a cold," he said in an interview. "It does all kinds of things to counter the effects of viruses." He said there was evidence that a deficiency in producing the protein could explain the enhanced susceptibility of at-risk patient groups to develop severe lower respiratory tract disease during respiratory viral infections. "Another quirk to coronavirus is that the disease itself suppresses the production of interferon-beta in the lungs, and it does this to evade the immune system," he said. The drug, which has already shown benefits in two trials for asthma, aims to boost the amount of interferon-beta in the lungs, helping either prevent or diminish cell damage and viral replication, he said. The pilot phase of the study has been given the green light by Britain's Medicines and Healthcare products Regulatory Agency and Health Research Authority. The study, which is expected to start imminently, will involve 100 COVID-19 patients in hospitals in Britain. Claim: Synairgen gets green light for coronavirus drug trial.

Ex Output:
British pharmaceutical company Synairgen said on Wednesday it had the go-ahead to test a drug that could boost the lung function of patients with coronavirus, potentially assisting in the global fight against the pandemic.